FDA clears Vertex's hepatitis C drug Incivek

Mon, 05/23/2011 - 6:17am
The Associated Press

The Food and Drug Administration approved Vertex Pharmaceuticals Inc.'s hepatitis C drug Incivek Monday, making Incivek the second new treatment to be approved in the last two weeks.

Incivek is a highly-anticipated pill that is expected to have annual sales in the billions. It is approved for patients who have some liver damage from hepatitis C who either have not been treated, or were not cured by other drugs. Incivek is a pill taken twice per day, making it more convenient than older intravenous therapies. The Cambridge, Mass., company has already started promoting the drug in advance of approval.

Incivek and Merck & Co's Victrelis, which was approved earlier this month, are the first new treatments for the liver disease to be approved in 20 years.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.